Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
Celcuity Inc. (CELC), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on June 28, 2021. The filing reports the entry into a material definitive agreement regarding a public equity offering.
Key Financial Metrics and Transaction Details
- Offering Size: 2,250,000 shares of common stock at $25.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 337,500 shares.
- Net Proceeds: Approximately $52.75 million after deducting underwriting discounts and offering expenses.
- Use of Proceeds: Working capital, general corporate purposes, capital expenditures, research and development, clinical trial expenditures, and business development.
- Expected Closing: July 1, 2021, subject to customary conditions.
Note: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes
The primary material change is the execution of an Underwriting Agreement with Jefferies LLC and Cowen and Company, LLC. This transaction represents a significant capital raise intended to fund the company's operational and clinical expansion.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to support clinical trial expenditures and business development activities. The offering was made pursuant to an effective registration statement on Form S-3. The Underwriting Agreement includes customary representations, warranties, covenants, and indemnification obligations. No specific risks or contingencies beyond standard underwriting terms were detailed in the text of this filing.
Key Facts for Investor Verification
- Verify the final closing date of the offering (expected July 1, 2021).
- Confirm whether the underwriters exercised the 337,500 share over-allotment option.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
- Check subsequent filings for the actual net proceeds received and the specific allocation of funds.